Worth reading
48Recurring
Scored from 4 of 5 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
1216100
sharesWording
Conditional
How definitive the wording is.Details of issuance or disposal
Acquisition and cancellation of the Fifth Series of Stock Acquisition Rights
Intended allottee
Cantor Fitzgerald Europe (counterparty to the acquisition)
Terms of the stock acquisition rights
Number of Stock Acquisition Rights
Total issued: approximately 7.6 million shares equivalent (number: Not disclosed); unexercised balance: 12,161 rights (equivalent to 1,216,100 shares)
Procedures under the Corporate Code of Conduct
The Company will give written notice of the acquisition to the counterparty on 24 June 2026 pursuant to Paragraph 14(1) of the issuance terms.
Most recent equity financing
Issuance of the Fifth Series of Stock Acquisition Rights, resolved on 13 December 2024: approximately 7.6 million shares equivalent; unexercised balance subject to acquisition: 12,161 rights (equivalent to 1,216,100 shares)
Impact on Business Performance
The impact on consolidated results for the fiscal year ending March 2027 will be minor. The transaction is expected to eliminate dilution concerns and potential selling pressure equivalent to approximately 1.2 million shares in terms of supply and demand, contributing to higher EPS over the medium to long term and further enhancement of shareholder value.
| Item | Details |
|---|---|
| Type of issuance or disposal | Acquisition and cancellation of the Fifth Series of Stock Acquisition Rights |
| Intended allottee | Cantor Fitzgerald Europe (counterparty to the acquisition) |
| Number of Stock Acquisition Rights | Total issued: approximately 7.6 million shares equivalent (number: Not disclosed); unexercised balance: 12,161 rights (equivalent to 1,216,100 shares) |
| Procedures under the Corporate Code of Conduct | The Company will give written notice of the acquisition to the counterparty on 24 June 2026 pursuant to Paragraph 14(1) of the issuance terms. |
| Most recent equity financing | Issuance of the Fifth Series of Stock Acquisition Rights, resolved on 13 December 2024: approximately 7.6 million shares equivalent; unexercised balance subject to acquisition: 12,161 rights (equivalent to 1,216,100 shares) |
| Impact on Business Performance | The impact on consolidated results for the fiscal year ending March 2027 will be minor. The transaction is expected to eliminate dilution concerns and potential selling pressure equivalent to approximately 1.2 million shares in terms of supply and demand, contributing to higher EPS over the medium to long term and further enhancement of shareholder value. |
Items this document does not state (22)
Number of shares to be issued or disposed ofIssue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise priceExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offering
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Company has established a structure to fund its required capital needs through lower-cost and more stable indirect financing following the restructuring of its bank facilities; these stock acquisition rights have adequately fulfilled their original role as a means of raising funds; and market concerns about dilution from the unexercised balance had been suppressing the underlying valuation of the Company's shares.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.